

Antibody-drug analogues



As the main part of the modern biomedical industry, antibody drugs account for about 50% of global biopharmaceutical market. Antibody biosimilars are emerging biopharmaceutic market. Since the best-selling patents for several antibody drugs have expired, this provide an opportunity for antibody-drug analogues. Antibody-drug analogues and biological original drugs contain similar active substances, which are similar in quality, safety and effectiveness, there is no difference in clinical significance. On November 7, 2019, the first adalimumab biosimilar drug BAT1406 was approved for marketing in China, which accelerated the development of antibody drugs.

AtaGenix is now launching antibody-drug analogues to support the development of antibody drugs.

Catalog of antibody-drug analogues (Section)


Cata No.	INN	Species	Specificity target name [species]
ATAD00001	alemtuzumab	Humanized	CD52 [Homo sapiens]
ATAD00002	ruplizumab	Humanized	CD40LG [Homo sapiens]
ATAD00003	apolizumab	Humanized	HLA-DRB [Homo sapiens]
ATAD00004	bevacizumab	Humanized	VEGFA [Homo sapiens]
ATAD00005	daclizumab	Humanized	IL2RA [Homo sapiens]
ATAD00006	eculizumab	Humanized	C5 [Homo sapiens]
ATAD00007	efalizumab	Humanized	ITGAL [Homo sapiens]
ATAD00008	matuzumab	Humanized	EGFR [Homo sapiens]
ATAD00009	epratuzumab	Humanized	CD22 [Homo sapiens]
ATAD00010	fontolizumab	Humanized	IFNG [Homo sapiens]
ATAD00011	gemtuzumab	Humanized	CD33 [Homo sapiens]
ATAD00013	lintuzumab	Humanized	CD33 [Homo sapiens]
ATAD00014	lorvotuzumab mertansine	Humanized	NCAM1 [Homo sapiens]
ATAD00015	labetuzumab	Humanized	CEACAM5 [Homo sapiens]

ATAD00016	amatuximab	Chimeric	MSLN [Homo sapiens]
ATAD00017	naptumomab estafenatox	Mus musculus	TPBG [Homo]
ATAD00018	siplizumab	Humanized	CD2 [Homo sapiens]
ATAD00019	motavizumab	Humanized	RSV glycoprotein F [Respiratory syncytial virus]
ATAD00020	natalizumab	Humanized	ITGA4 [Homo sapiens]
ATAD00021	nimotuzumab	Humanized	EGFR [Homo sapiens]
ATAD00022	omalizumab	Humanized	IGHE [Homo sapiens]
ATAD00023	cedelizumab	Humanized	CD4 [Homo sapiens]
ATAD00024	palivizumab	Humanized	RSV glycoprotein F [Respiratory syncytial virus]
ATAD00025	pertuzumab	Humanized	ERBB2 [Homo sapiens]
ATAD00026	pexelizumab	Humanized	C5 [Homo sapiens]
ATAD00027	sevirumab	Homo sapiens	HCMV envelope glycoprotein H [Human herpesvirus 5]
ATAD00028	ranibizumab	Humanized	VEGFA [Homo sapiens]
ATAD00029	felvizumab	Humanized	RSV glycoprotein F [Respiratory syncytial virus]
ATAD00030	mepolizumab	Humanized	IL5 [Homo sapiens]
ATAD00031	pascolizumab	Humanized	IL4 [Homo sapiens]
ATAD00032	foravirumab	Homo sapiens	RV glycoprotein, antigenic site III [Rabies virus]
ATAD00033	rafivirumab	Homo sapiens	RV glycoprotein, antigenic site I [Rabies virus]
ATAD00034	visilizumab	Humanized	CD3E [Homo sapiens]
ATAD00035	blinatumomab	Mus musculus	CD19 [Homo sapiens]; CD3E [Homo sapiens]; bispecific
ATAD00036	gevokizumab	Humanized	IL1B [Homo sapiens]
ATAD00037	tadocizumab	Humanized	ITGA2B_ITGB3 platelet [Homo sapiens]
ATAD00038	YFC51.1mab	Humanized	ITGB2 [Homo sapiens]
ATAD00039	YTH12.5	Humanized	CD3E [Homo sapiens]
ATAD00041	14F7	Mus musculus	NeuGcGM3 [Homo sapiens]
ATAD00043	HuJ591-GSmab	Mus musculus	FOLH1 [Homo sapiens]
ATAD00045	gavilimomab	Mus musculus	BSG [Homo sapiens]
ATAD00046	arcitumomab	Mus musculus	CEACAM5 [Homo sapiens]
ATAD00047	capromab	Mus musculus	FOLH1 [Homo sapiens]
ATAD00048	Campath-9H	Mus musculus, Humanized	CD4 [Homo sapiens]
ATAD00049	edobacomab	Mus musculus	LPS [Gram negative bacteria]
ATAD00050	edrecolomab	Mus musculus	EPCAM [Homo sapiens]
ATAD00051	enlimomab	Mus musculus	ICAM1 [Homo sapiens]
ATAD00052	HNK20mab	Mus musculus	RSV glycoprotein F [Respiratory syncytial virus]

ATAD00053	ibritumomab tiuxetan	Mus musculus	MS4A1 [Homo sapiens]
ATAD00054	igovomab	Mus musculus	MUC16 [Homo sapiens]
ATAD00055	imciromab	Mus musculus	myosin, cardiac [Homo sapiens]
ATAD00056	ImmuRAIT-LL2mab	Mus musculus	CD22 [Homo sapiens]
ATAD00057	inolimomab	Mus musculus	IL2RA [Homo sapiens]
ATAD00058	afelimomab	Mus musculus	TNF [Homo sapiens]
ATAD00059	T10B9.1A-31	Mus musculus	TR [Homo sapiens]
ATAD00060	mitumomab	Mus musculus	ganglioside GD3 [Homo sapiens]
ATAD00061	biciromab	Mus musculus	fibrin II beta chain [Homo sapiens]
ATAD00062	muromonab-CD3 technetium	Mus musculus	CD3E [Homo sapiens]
ATAD00063	nofetumomab merpentan	Humanized	IL3RA [Homo sapiens]
ATAD00064	odulimomab	Mus musculus	ITGAL [Homo sapiens]
ATAD00065	milatuzumab	Humanized	CD74 [Homo sapiens]
ATAD00066	oregovomab	Mus musculus	MUC16 [Homo sapiens]

· For research use only

AtaGenix wholeheartedly provide you with satisfactory scientific research services



AtaGenix Laboratory

AtaGenix developed the most productive mammalian expression system for transient recombinant antibody production. With the support of pATX vectors and modified 293 & CHO cell lines, the antibody expression level accesses 1g/L. In the meantime, the dedicated endotoxin control and removal product line achieves pharmaceutical-grade antibody drug production. (<0.1EU/mg)

AtaGenix offers one-stop solution to monoclonal antibody drug. Only needed the antibody drug's name, we will custom produce the antibody-drug analogues accordingly.

Enquire and Order

Tel: (0086)27-87433958 Web: www.atagenix.com Email: info@atagenix.com

Wuhan Institute of Biotechnology, B8, Biolake, 666 GaoXin Road, Wuhan, Hubei, China